Mesoblast Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEOBF research report →
About the company
Mesoblast Limited, an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operations spanning the United States, Australia, Singapore, the United Kingdom, and Switzerland, the firm leverages a proprietary regenerative medicine platform based on specialized mesenchymal lineage cells. This technology underpins treatments for a wide spectrum of conditions, including cardiovascular, spinal orthopedic, oncological, hematological, immune-mediated, and inflammatory diseases.
- CEO
- Silviu Itescu
- IPO
- 2010
- Employees
- 73
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $2.00B
- P/E
- -19.43
- P/S
- 28.28
- P/B
- 3.21
- EV/EBITDA
- -28.83
- Div Yield
- 0.00%
- Gross Margin
- -53.34%
- Op Margin
- -223.08%
- Net Margin
- -144.33%
- ROE
- -16.10%
- ROIC
- -20.16%
- Revenue
- $17.20M · 191.39%
- Net Income
- $-102,142,000 · -16.13%
- EPS
- $-0.09 · 3.59%
- Op Income
- $-62,443,000
- FCF YoY
- -3.88%
- 52W High
- $2.59
- 52W Low
- $0.97
- 50D MA
- $1.65
- 200D MA
- $1.60
- Beta
- 0.80
- Avg Volume
- 272
Get TickerSpark's AI analysis on MEOBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MEOBF coverage
Recent articles, reports, and earnings notes.
No research on MEOBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MEOBF report →Similar companies
Peers in the same neighborhood.